Brown Brothers Harriman & Co. Has $46 Million Holdings in Certara, Inc. $CERT

Brown Brothers Harriman & Co. boosted its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 34.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,764,034 shares of the company’s stock after acquiring an additional 972,669 shares during the quarter. Brown Brothers Harriman & Co. owned 2.36% of Certara worth $45,996,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Associated Banc Corp increased its position in shares of Certara by 9.7% during the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock worth $146,000 after buying an additional 1,051 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Certara by 2.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock valued at $535,000 after buying an additional 1,136 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after buying an additional 1,153 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the last quarter. Finally, Corient Private Wealth LLC increased its position in shares of Certara by 11.1% during the second quarter. Corient Private Wealth LLC now owns 12,299 shares of the company’s stock worth $144,000 after acquiring an additional 1,232 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CERT has been the topic of a number of recent analyst reports. Stephens dropped their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Leerink Partners restated an “outperform” rating and issued a $10.00 price objective on shares of Certara in a research note on Thursday, February 26th. Rothschild & Co Redburn set a $10.00 target price on Certara in a research report on Friday, November 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Certara in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $11.10.

Certara Stock Performance

NASDAQ:CERT opened at $6.65 on Friday. The business’s fifty day moving average is $7.98 and its 200 day moving average is $9.62. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -665.00 and a beta of 1.50. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. Certara, Inc. has a 52-week low of $6.04 and a 52-week high of $15.38.

Certara (NASDAQ:CERT) last issued its earnings results on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $103.65 million during the quarter, compared to the consensus estimate of $103.23 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Research analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.